TABLE 1.
Parametera | Estimate | 95% confidence interval |
---|---|---|
Econ | 98.99 | 97.80–100.2 |
IC50,IND | 146.9 | 128.3–165.6 |
mIND | 1.711 | 1.393–2.030 |
IC50,AZT | 118.4 | 108.2–128.6 |
mAZT | 12.89 | 5.576–20.20 |
IC50,3TC | 1,029.0 | 1,018–1,041 |
m3TC | 68.75 | 36,90–100.6 |
αIND,AZT | 0.0001301 | −0.6191–0.6194 |
αIND,3TC | 0.6881 | −0.05189–1.428 |
αAZT,3TC | 0.9692 | 0.9417–0.9966 |
αIND,AZT,3TC | 8.94 | 3.434–14.45 |
Econ, effect seen in the absence of drug (percent); IC50, concentration of drug necessary to reduce the HIV turnover by half when used alone (nanomolar); m, slope parameter, corresponding to the rate of rise of effect with increasing drug concentration; α, interaction.